Wed. Oct 27th, 2021

Oncology is one of the most complicated segments of medical science. It is the branch of medical science that deals with the prevention, diagnosis and treatment of cancer.

The oncology process requires precision instruments to remove cancer cells from the human body.

The oncology market has experienced strong growth in recent years. For this reason, this market is experiencing a large inflow of capital and the support of the governing bodies.

One of the many companies that has experienced growth is Repare Therapeutics Inc.

Based in Canada, Repare Therapeutics is an industry-leading oncology company dedicated to precision in clinical stages.

An overview of Repare Therapeutics Inc.

Repare Therapeutics Inc. is an oncology company dedicated to the development of precision therapeutic products. The company uses the CRISPR-enabled SNIPRx platform for the discovery and development of cancer-targeted therapies.

These therapies focus on detecting instability in genomes, which also include repairs in DNA damage.

With Repair Therapeutics, it has become easy to deal with tumor biology that was not previously addressed. The company suggests using an approach focused on specific genetics and allowing it to function in multiple tumors.

Genetic stratification of patients allows for higher response rates.

Repair Therapeutics ’approach to therapeutic novelties

With its platform, Repare Therapeutics Inc. is developing a number of SL product candidates. One of them is its product, RP-3500, which is an oral small cell inhibitor that is used to treat solid tumors that contain alterations in genomes related to DNA damage repair.

The company uses gene editing technology alongside its method of goal discovery with clinical computing, high-resolution protein crystallography, and computational biology.

It allows patients to improve cancer treatment, both with single therapy and in combination with existing medications and treatments.

Perspectives of the Repair Therapeutics Company

To learn more about the business, you need to know what it aims to provide to the community. Its mission, ethics, and scientific methodology play a crucial role in understanding Repare Therapeutics ’unique approach.


Repair Therapeutics is a pioneering synthetic lethality to develop a new therapy. They target specific tumor vulnerabilities in genetically defined hospital populations.

The company’s initial goal is to focus on new targeted therapies in cancer types that contain a defective response to DNA damage (DDR) or functions related to genome instability.


The Repair Therapeutics Board of Directors has set high standards for employees and employees of the company. What is included in this doctrine is the importance of great corporate governance.

The Board of Directors must serve as a smart trustee for the company’s shareholders and oversee the company’s business management.

To exercise responsibility and functions, the Company’s Board of Directors follows a set of rules and regulations described in the guidelines.

Company guidelines are subject to additional modifications and regulations. As and when the Board of Directors deems it appropriate, these modifications are made. They are made in the best interests of the company or as required by applicable laws and regulations.


Repair Therapeutics is an industry-leading oncology company dedicated to precision in clinical stages. The company is considered a leader in the field of genomic instability and synthetic lethality (SL) detection approaches.

The company’s management team is highly qualified and has extensive experience in drug discovery and development.

The co-founders and other members of the executive team have extensive aggregate experience in oncology drug discovery and development.

Repair Therapeutics Inc. Finance

Founded in 2016, Repare Therapeutics Inc is a public company. Over the course of two rounds, Repare Therapeutics has managed to fund a total of $ 150.5 million. Its last funding was raised on September 4, 2019 from a Series B round.

Repair Therapeutics ’estimated annual revenue is currently $ 15.8 million annually.

The estimated revenue per Repare Therapeutics employee is $ 155,000.

Cash and restricted cash as of June 30, 2020 were $ 370.1 million.

  • Research and development expenses, net of tax credits (non-R&D)

Net R&D expenditures were $ 9.0 million and $ 17.6 million for the three- and six-month periods ended June 30, 2020, compared to $ 4.9 million and $ 8.6 million, respectively. dollars in the same periods of the previous year, respectively.

  • General and administrative expenses (G&A)

G&A expenses were $ 3.4 million and $ 5.4 million for the three- and six-month periods ended June 30, 2020, compared to $ 1 million and $ 2.1 million in the same periods. the previous year, respectively.

Repair Therapeutics actions

The stock symbol of Repare Therapeutics is RPTX. The company’s shares are listed on the Nasdaq Global Select Market. Repair Therapeutics ’CUSIP number is 760273 102. The company went public on September 6, 2016.

An RPTX share can currently be purchased for approximately $ 33.14.

Repair Therapeutics ’initial public offering was on June 18, 2020. The money raised on the IPO was $ 220 million.

Major investing institutions in Repare Therapeutics

  • BVF Inc.
  • Orbimed Advisors LLC.
  • FMR, LLC
  • Redmile Group, LLC
  • MPM Asset Management, LLC
  • CHI Advisors LLC
  • ARK Investment Management, LLC
  • Logos Global Management LP
  • Artal Group SA

Restorative Therapy: Progress

The company systematically analyzes genomic data from about 60,000 tumor samples. The samples are then identified as the initial set of tumor genomic alterations, which are called tumor lesions.

They complete a SNIPRx display platform to identify previously reported targets or even unreported ones for each of these tumor lesions.

SNIPRx display campaigns identify multiple potential targets. This allows them to prioritize and select targets for advancement in drug discovery based on a systematic and proprietary set of criteria.


Repair Therapeutics Inc. is a growing name in the cancer market. And it is because of its unique scientific methodology and approach. While the company faces stiff competition from competitors, Repare Therapeutics Inc. definitely has a promising path.

Sometimes we include links to online retail stores. If you click on one and make a purchase we may receive a small commission.

Source link

Leave a Reply